Twelve-month follow-up data from a clinical trial of OrbusNeich’s Genous stent has revealed that the device is safe and effective.

The Genous stent is an endothelial progenitor cell capture technology that enhances the natural healing of the vessel wall.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The multi-centre prospective clinical study, called e-HEALING, included 4,939 patients with at least one lesion suitable for non-urgent percutaneous coronary intervention.

Target vessel failure occurred in 11.7% of patients over the age of 75, in 8.8% of patients between the ages of 65 and 74, and in 7% of patients younger than 65.

Secondary endpoint includes composite of cardiac death, myocardial infarction and the target lesion revascularization rate.

 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact